Utiva Probiotic strains are all locally grown and produced. Contains 30 Billion CFU with a guaranteed 12 Billion CFU at time of expiry. It is shelf-stable and does not require refrigeration.

Ingredients

Per Capsule

Medicinal Ingredients

Lactobacillus rhamnosus (GG) (whole cell) 6 billion CFU Bifidobacterium animalis subsp. Lacti (A026) (whole cell) 2.4 billion CFU Lactococcus lactis (A200) (whole cell) 1.2 billion CFU Lactobacillus acidophilus (A118) (whole cell) 1.08 billion CFU Lactobacillus plantarum (A138) (whole cell) 0.6 billion CFU Lactobacillus casei (A179) (whole cell) 0.3 billion CFU Lactobacillus paracasei (A234) (whole cell) 0.3 billion CFU Lactobacillus gasseri (A237) (whole cell) 0.12 billion CFU

Non-Medicinal Ingredients

Maltodextrin, maize starch, fructooligosaccharides, magnesium stearate, silicon dioxide, vegetable capsule.

Adults: 1 capsule daily. If on antibiotics, take Probiotic at least 2-3 hours before or after.
Consult a physician prior to use if you have fever, vomiting, bloody diarrhea, or severe abdominal pain. If symptoms of digestive upset (e.g., diarrhea) occur, worsen, or persist beyond 3 days, discontinue use and consult a physician. Keep out of reach of children.

Contraindications:
Do not use this product if you have an immune-compromised condition (e.g., AIDS, lymphoma, patients undergoing long-term corticosteroid treatment).

What makes Utiva Probiotic different?

What makes Utiva Probiotic different?

Utiva uses proprietary delayed release capsules

The probiotic strains are protected in our proprietary delayed release capsules which are vegetarian capsules specially designed to resist stomach acid and release directly in the intestinal tract. It also enhances stability and minimizes any taste and odour.

Clinical studies

01

In a randomized clinical trial, Lactobacillus rhamnosus GG was shown to be effective in reducing side effects related to antibiotics.

45%

reduction in the risk of antibiotic-related diarrhea in patients given L. rhamnosus GG.

02

In a meta-analysis of randomized controlled trials, it was found that Lactobacillus spp. probiotics was effective for preventing diarrhea due to Clostridium difficile.

75%

pooled relative risk reduction of C. difficile-associated diarrhea with probiotics containing Lactobacillus spp.

03

Research shows that Lactobacillus and Bifidobacterium probiotic strains can prevent the adherence, growth, and colonization of uropathogenic bacteria.

6

Target pathogens were studied and healthy microbial populations of lactobacillus and bifidobacterium showed a strong inhibitory effect against E. coli.

UTI prevention related talks

Dr. Susan Oakley
Shelley Morgan
Dr. Lysanne Campeau
Dr. Adam Holzberg
Dr. Susan Oakley
Dr. Bilal Chughtai
Dr. Yana Barbalat
Dr. Ashley Girard

For more information or wholesale inquiries, please feel free to reach out to us.

For more information or wholesale inquiries, please feel free to reach out to us.